PH12012501906A1 - Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof - Google Patents

Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof

Info

Publication number
PH12012501906A1
PH12012501906A1 PH1/2012/501906A PH12012501906A PH12012501906A1 PH 12012501906 A1 PH12012501906 A1 PH 12012501906A1 PH 12012501906 A PH12012501906 A PH 12012501906A PH 12012501906 A1 PH12012501906 A1 PH 12012501906A1
Authority
PH
Philippines
Prior art keywords
cpa
prodrugs
derivatives
cyclopentyladenosine
humans
Prior art date
Application number
PH1/2012/501906A
Other languages
English (en)
Inventor
Prakash Jagtap
Norman N Kim
Thomas G Mccauley
William K Mcvicar
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of PH12012501906A1 publication Critical patent/PH12012501906A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PH1/2012/501906A 2010-03-26 2011-03-25 Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof PH12012501906A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31810510P 2010-03-26 2010-03-26
PCT/US2011/030009 WO2011119969A1 (en) 2010-03-26 2011-03-25 Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof

Publications (1)

Publication Number Publication Date
PH12012501906A1 true PH12012501906A1 (en) 2013-01-14

Family

ID=44673656

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2012/501906A PH12012501906A1 (en) 2010-03-26 2011-03-25 Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof

Country Status (16)

Country Link
US (4) US8476247B2 (enExample)
EP (1) EP2569325A4 (enExample)
JP (2) JP2013523739A (enExample)
KR (1) KR20130029050A (enExample)
CN (1) CN102933593A (enExample)
AU (1) AU2011230580A1 (enExample)
BR (1) BR112012023749A2 (enExample)
CA (1) CA2792266A1 (enExample)
CL (1) CL2012002613A1 (enExample)
CO (1) CO6630141A2 (enExample)
EA (1) EA201290958A1 (enExample)
MX (1) MX2012010724A (enExample)
PH (1) PH12012501906A1 (enExample)
SG (1) SG184221A1 (enExample)
WO (1) WO2011119969A1 (enExample)
ZA (1) ZA201207090B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02608B (me) * 2010-01-11 2017-06-20 Inotek Pharmaceuticals Corp Kombinacija, komplet i postupak snižavanja intraokularnog pritiska
CN102933593A (zh) * 2010-03-26 2013-02-13 伊诺泰克制药公司 使用n6-环戊基腺苷（cpa）、cpa衍生物或其前药降低人眼内压的方法
US9278991B2 (en) * 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
BR112015021870A2 (pt) 2013-03-15 2017-07-18 Inotek Pharmaceuticals Corp formulações oftálmicas
US20160158267A1 (en) * 2014-12-03 2016-06-09 Inotek Pharmaceuticals Corporation Methods of preventing, reducing or treating macular degeneration
CN119365476A (zh) * 2022-06-17 2025-01-24 上海森辉医药有限公司 一种环戊基腺苷衍生物及其药物用途

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4935635B1 (enExample) 1970-12-28 1974-09-25
CH563405A5 (enExample) 1971-09-10 1975-06-30 Duschinsky Robert Dr Schweiz I
DE2226295A1 (de) 1972-05-30 1973-12-20 Henning Berlin Gmbh Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben
DE2342479A1 (de) 1973-08-23 1975-03-13 Merck Patent Gmbh Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung
GB2001976B (en) 1977-08-03 1982-03-10 Yamasa Shoyu Kk S-adenosyl-l-methionine compositions and production thereof
US4849311A (en) 1986-09-24 1989-07-18 Toa Nenryo Kogyo Kabushiki Kaisha Immobilized electrolyte membrane
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2062102T5 (es) 1988-09-06 2004-12-01 Pharmacia Ab Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
JP3020580B2 (ja) 1990-09-28 2000-03-15 株式会社日立製作所 マイクロ波プラズマ処理装置
US5206222A (en) 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
HU212570B (en) 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5407793A (en) 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
US5278150A (en) 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
DK62692D0 (enExample) 1992-05-14 1992-05-14 Novo Nordisk As
WO1994002497A1 (en) 1992-07-15 1994-02-03 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sulfo-derivatives of adenosine
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5338430A (en) 1992-12-23 1994-08-16 Minnesota Mining And Manufacturing Company Nanostructured electrode membranes
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
WO1995002604A1 (en) 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5620676A (en) 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
EP0704215A3 (en) 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
CN1164122A (zh) 1996-03-01 1997-11-05 株式会社日立制作所 等离子处理机及其处理方法
AU2022497A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2289731A1 (en) 1997-05-09 1998-11-12 The United States Of America, Represented By The Secretary, Department O F Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
CA2306096A1 (en) 1997-10-15 1999-04-22 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
AU1363699A (en) 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2775901B1 (fr) 1998-03-13 2000-07-21 Logeais Labor Jacques Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
EP1096975B1 (en) 1998-07-16 2005-03-16 The Trustees Of The University Of Pennsylvania Use of a3 adenosine receptor antagonists in the manufacture of a medicament for reducing intraocular pressure
CA2347512C (en) 1998-10-16 2005-12-06 Pfizer Inc. Adenine derivatives
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
WO2000078776A2 (en) 1999-06-22 2000-12-28 Cv Therapeutics, Inc. Thiophene a2a receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US6368573B1 (en) 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6258793B1 (en) 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
GB9930071D0 (en) 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US20010051612A1 (en) 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US20030010454A1 (en) 2000-03-27 2003-01-16 Bailey Andrew D. Method and apparatus for varying a magnetic field to control a volume of a plasma
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
EP1307191A2 (en) 2000-07-28 2003-05-07 Inspire Pharmaceuticals, Inc. Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
EP1365776B1 (en) 2001-01-16 2005-04-13 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
JP2004537401A (ja) 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション 疎水性薬物の微粉砕方法
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
CA2482928A1 (en) 2002-04-18 2003-10-30 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
EP1497420A4 (en) 2002-04-30 2005-04-27 Alcon Inc AGENTS THAT REGULATE, RESTRICT OR MODULATE THE ACTIVITY AND / OR EXPRESSION OF BIND WEAVE GROWTH FACTOR (CTGF) AS UNIQUE MEDICAMENTS BOTH TO REDUCE EYESPRINTS AND TREAT GLACCOMPETOSIS RETINOPATHIES / OPTIC NEUROPATHIES
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20060034941A1 (en) 2002-12-23 2006-02-16 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
GB2436255B (en) 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
CA2468664C (en) 2003-06-03 2012-03-06 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
AU2005207037A1 (en) 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
CN101010085B (zh) 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
AU2005249430B2 (en) 2004-05-26 2011-06-23 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
CN1980946A (zh) 2004-07-12 2007-06-13 Cv医药有限公司 用于制备a1腺苷受体激动剂的方法
US20090220516A1 (en) 2005-06-22 2009-09-03 Alan Laties Neuroprotection of retinal ganglion cells
AU2006320578B2 (en) 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
EP2397148A3 (en) 2006-02-02 2012-04-25 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
JP2009530393A (ja) 2006-03-23 2009-08-27 イノテック ファーマシューティカルズ コーポレイション プリン化合物およびその使用方法
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US20080050335A1 (en) 2006-07-25 2008-02-28 Osmotica Corp. Ophthalmic Solutions
WO2008045330A2 (en) * 2006-10-06 2008-04-17 The Trustees Of The University Of Pennsylvania Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure
UA95819C2 (ru) 2006-11-10 2011-09-12 Басф Се Кристаллическая модификация iv фипронила, способ ее получения, применения, способы получения кристаллических модификаций v и i, пестицидная или паразитицидная композиция, способ контроля вредителей, способ защиты растения от заражения или нападения вредителей, способ защиты семян и способ лечения, контроля, предотвращения или защиты животных от заражения или инфекции паразитами
CN101657212B (zh) 2006-12-05 2014-03-19 皇家学习促进会/麦吉尔大学 Trk受体调节剂的使用方法
JP2008266143A (ja) 2007-04-16 2008-11-06 Santen Pharmaceut Co Ltd アデノシン誘導体を有効成分として含有する緑内障治療剤
EP2205071B1 (en) 2007-10-11 2015-07-22 Biogen MA Inc. Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma
US20100272711A1 (en) 2007-12-12 2010-10-28 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
CN101983062A (zh) 2008-02-07 2011-03-02 吉利德帕洛阿尔托股份有限公司 提高abca-1的化合物及其用途
CA3019967A1 (en) 2008-11-13 2010-05-20 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of bmp-6
HUE028068T2 (en) * 2009-05-01 2016-11-28 Inotek Pharmaceuticals Corp A method for reducing the pressure in a human patient
JP2013508420A (ja) * 2009-10-26 2013-03-07 イノテック ファーマシューティカルズ コーポレイション 点眼製剤およびその製造方法
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
ME02608B (me) 2010-01-11 2017-06-20 Inotek Pharmaceuticals Corp Kombinacija, komplet i postupak snižavanja intraokularnog pritiska
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
LT2555775T (lt) * 2010-03-19 2017-04-25 Inotek Pharmaceuticals Corporation Adenozino a1 agonistų ir karboanhidrazės inhibitorių derinio kompozicijos, skirtos akispūdžio mažinimui
CN102958526A (zh) 2010-03-19 2013-03-06 伊诺泰克制药公司 用于降低眼内压的腺苷A1激动剂与非选择性β-肾上腺素能受体阻断剂的组合型组合物
CN102933593A (zh) * 2010-03-26 2013-02-13 伊诺泰克制药公司 使用n6-环戊基腺苷（cpa）、cpa衍生物或其前药降低人眼内压的方法
BR112012023747A2 (pt) 2010-03-26 2016-08-23 Inotek Pharmaceuticals Corp compostos de adenosina e seu uso
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
WO2014152733A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation A method of providing ocular neuroprotection
BR112015021870A2 (pt) * 2013-03-15 2017-07-18 Inotek Pharmaceuticals Corp formulações oftálmicas

Also Published As

Publication number Publication date
BR112012023749A2 (pt) 2016-08-23
EA201290958A1 (ru) 2013-04-30
US8476247B2 (en) 2013-07-02
CA2792266A1 (en) 2011-09-29
MX2012010724A (es) 2012-11-12
CN102933593A (zh) 2013-02-13
WO2011119969A1 (en) 2011-09-29
EP2569325A4 (en) 2013-10-09
ZA201207090B (en) 2014-03-26
US20150080330A1 (en) 2015-03-19
AU2011230580A1 (en) 2012-10-11
CO6630141A2 (es) 2013-03-01
KR20130029050A (ko) 2013-03-21
US9289383B2 (en) 2016-03-22
US20110245195A1 (en) 2011-10-06
US8895530B2 (en) 2014-11-25
EP2569325A1 (en) 2013-03-20
US20160158268A1 (en) 2016-06-09
JP2016147918A (ja) 2016-08-18
JP2013523739A (ja) 2013-06-17
US20140018314A1 (en) 2014-01-16
SG184221A1 (en) 2012-10-30
CL2012002613A1 (es) 2012-12-21

Similar Documents

Publication Publication Date Title
SG184221A1 (en) Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
EA201790889A1 (ru) Офтальмологический раствор
MY159463A (en) Method and composition for treating ocular hypertension and glaucoma
MY171920A (en) Prevention and treatment of ocular conditions
NZ705624A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
MX2010002617A (es) Implantes lagrimales y metodos relacionados.
PH12016501357B1 (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
MY159244A (en) Method of reducing intraocular pressure in humans
WO2013115861A3 (en) Method and apparatus for treating an ocular disorder
HK1198811A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
MX2023011426A (es) Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
BR112012028437A2 (pt) solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
EP4420726A3 (en) Fixed dose combination of bromonidine and timolol
WO2010141586A3 (en) Therapeutic ophthalmic emulsions
PH12012501907A1 (en) Adenosine compounds and thier use thereof
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
MY178169A (en) Topical ophthalmic peptide formulation
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX2019005321A (es) Derivados de prostaglandina que liberan oxido nitrico para el tratamiento de glaucoma de tension normal.
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.
MX375963B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
WO2012024419A3 (en) Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma